Stay updated on Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications section wording was updated to clarify PubMed autofill may not reflect the study, the previous PubMed-generated note was removed, and the revision number at the bottom was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe government funding lapse notice was removed from the page. It previously warned that information might not be up to date and inquiries might not be processed until appropriations were enacted.SummaryDifference0.1%

- Check42 days agoChange DetectedCompared with the prior screenshot, there are no changes to core study information (title, eligibility criteria, outcomes, enrollment); observed differences appear to be minor UI/layout refinements. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check71 days agoChange DetectedLocation region renamed (Rhône-Alpes -> Auvergne-Rhône-Alpes) and revision updated to v3.2.0; Lyon address adjusted to the new region.SummaryDifference5%

- Check78 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' element was removed as a minor UI change; overall, the substantive update is the version bump.SummaryDifference0.1%

Stay in the know with updates to Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.